Echosens joins the American Liver Foundation in observance of Liver Cancer Awareness Month, urging increased awareness of non-alcoholic fatty liver disease (NAFLD) and its more severe form called non-alcoholic steatohepatitis (NASH
This white paper examines the impact of NAFLD and NASH as both a medical and economic crisis among military and civilian populations, and highlights the VA’s strategy to eradicate liver disease, including its broadened contract with Echosens to include the FibroScan mini+ portable technology
Stephen Harrison, MD, from Pinnacle Clinical Research, discusses how to educate patients on nonalcoholic fatty liver disease (NAFLD), lifestyle changes that are crucial for patients with NAFLD, and more.
Physicians and administrators at some of the nation’s leading Federally Qualified Health Centers (FQHCs) now have the ability to quickly and easily assess liver health to better address the NAFLD epidemic
It’s startling to learn that over 30% of the U.S. population has some degree of non-alcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver and the most common type of liver disease in the Western world
Stephen Harrison, MD, from Pinnacle Clinical Research, discusses how specialists can help educate primary care physicians (PCPs) more on non-alcoholic fatty liver disease (NAFLD), the importance of PCPs recognizing which individuals with NAFLD can progress to more sever liver disease, and more.
A growing number of healthcare providers are adopting FibroScan, a non-invasive technology to examine patient’s liver at the point of care.